On September 11, 2020 Phost’in Therapeutics (Montpellier,France), a research-driven biopharmaceutical company developing N-glycosylation inhibitors as a First-in-Class immunotherapy for cancer treatment, reported that it will receive a €2.5 million funding from Bpifrance in addition to its recent Series-A round (Press release, Phost’in, SEP 11, 2020, View Source [SID1234565009]). This non-dilutive funding includes €2 million from Bpifrance’s Deeptech program, initiated by the French government, to boost highly innovative and breakthrough projects emerging from fundamental research and to strengthen the country’s competitive advantage in the field. Proceeds will be used to advance the regulatoryand early-clinical development ofPhost’in’s main program PhOx430 for the next two years. To date, Phost’in Therapeutics has raised a total of €16 million.The company has previously announced in April 2020a €10.3 million Series A round from an international syndicate of Life Science and Innovation Investors led by Remiges Ventures, providing the company resources to bring PhOx430 into clinical trials by 12 months with a focus on aggressive solid tumorssuch as Glioblastomas and Triple Negative Breast Cancers. A new and innovative player in the field of Glyco-Immuno-Oncology, Phost’in Therapeutics develops a class of highly potent anti-cancer NCEs (new chemical entities) targeting a key glycosylation mechanism responsible for immune response suppression. Karine Chorro, co-founder and CEO of Phost’in Therapeutics, said "Joining the deep tech community represents the recognition of our N-glycosylation inhibitors as a breakthrough disruptive innovation. Plus, it will enable us to largely accelerate the development of our main program PhOx430 towards clinical trials, for the full benefit of patients still suffering from very limited therapeutic options. We are very excitedto move forward in this next step with the support ofBpifrance." "At Bpifra nce,we work hard to identify and support disruptive technologies correlated with strong entrepreneurial spirit, in any world-changing fields that will be transformative for generations to come. We are enthusiastic about the cutting-edge science behindthe program,coming from years of academic researches in several top-level French institutes, and strongly believe in Phost’in’s capacity to deliver its first-in-class candidate to patients suffering from rare and aggressive cancers" noted Nadine Faedo, Regional Director at Bpifrance. "Therefore, we foresee Bpifrance as a long-term partner of choice for Phost’in to install its leadership in the field of Glyco-Immuno-Oncology".

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On September 11, 2020 Pacira BioSciences, Inc. (NASDAQ: PCRX) reported that it will present at the 2020 H.C. Wainwright 22nd Annual Global Investment Conference at 3:30 PM ET on Monday, September 14, 2020 (Press release, Pacira Pharmaceuticals, SEP 11, 2020, View Source [SID1234565027]). Live audio of the virtual event can be accessed by visiting the "Events" page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On September 11, 2020 Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, reported that Barry Quart, Pharm.D., President and Chief Executive Officer of Heron Therapeutics, will participate in a fireside chat at the Cantor Virtual Global Healthcare Conference on Thursday, September 17, 2020 at 1:20 p.m. EDT (Press release, Heron Therapeutics, SEP 11, 2020, View Source [SID1234565043]). The conference is being held in a virtual format.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the fireside chat will be available on the Company’s website at www.herontx.com in the Investor Resources section. A replay of the presentation will be archived on the site for 60 days.

On September 10, 2020 Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the "Company") reported that members of the senior management team will participate in fireside chats during the following upcoming virtual investor conferences (Press release, Aurinia Pharmaceuticals, SEP 10, 2020, View Source [SID1234564919]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright & Co. 22nd Annual Global Investment Conference on September 14, 2020 at 10:30 a.m. EDT. Register here
Cantor Virtual Global Healthcare Conference on September 16, 2020 at 4:00 p.m. EDT. Register here
Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 23, 2020 at 1:40 p.m. ET. Register here
In order to participate in the audio webcast, interested parties can register and access the live webcast under "News/Events" through the "Investors" section of the Aurinia corporate website at www.auriniapharma.com. A replay of the webcast will be available on Aurinia’s website.

On September 10, 2020 Varian (NYSE: VAR) reported the Goshen Center for Cancer Care in Goshen, Ind., treated its first patient with Ethos therapy, marking the first availability of this advanced cancer treatment in the state of Indiana (Press release, Varian Medical Systems, SEP 10, 2020, View Source [SID1234564937]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Ethos therapy system combines an image-guided radiation therapy (IGRT) powerhouse with artificial intelligence (AI) adaptive capabilities in one system, creating workflow efficiencies that benefit both patient and clinician. This new solution is designed to deliver an entire adaptive treatment in a typical 15-minute timeslot, from patient setup through treatment delivery, making it ideal for a busy center. Incorporating multi-modality images, the Ethos adaptive therapy provides the ability to personalize the patient’s treatment based on their anatomy and position at the time of treatment. The goal is to better target the tumor, enable more customized margins, and potentially improve overall outcomes with a reduction in dose to healthy tissue.

"In the 25 years I have been in the field of radiation oncology, adaptive radiotherapy is the most revolutionary technology I have seen," said John P. Lowden, MS, DABR, Medical Physicist, Goshen Center for Cancer Care. "Ethos allows community cancer centers like Goshen Center for Cancer Care to provide adaptive daily treatments in an affordable and efficient package that keeps patient-centered design at its core."

Ethos therapy has the potential to ensure that advanced treatment approaches are available to any patient regardless of their proximity to major metropolitan cities or academic medical centers. An AI-assisted adaptive therapy system with an intelligent optimization engine and guided workflow, such as Ethos, can move adaptive therapy from a specialty offering by large centers into the mainstream of care. Ethos also offers the flexibility to choose adaptive or non-adaptive therapy to maximize operational efficiencies.

"Every patient deserves personalized cancer care," said Chris Toth, president of Varian Oncology Systems. "Varian is honored to be working with Goshen Health as one of the first hospitals nationally to bring Ethos adaptive treatments to patients and help all of us move closer to creating a world without fear of cancer."

"Ethos adaptive planning is truly remarkable technology," said Chelsea Poscharsky, RTT, Goshen Center for Cancer Care. "Because Ethos enables the creation of on-table adaptive plans, patients who would normally spend an entire day with us to get their anatomy correct prior to treatment are able to be treated within a 15-20-minute time slot. All without sacrificing treatment effectiveness or increasing patient side effects."